{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:12Z","timestamp":1792611672884,"version":"4.5.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.2169\/internalmedicine.3757-24","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:10:51Z","timestamp":1724796651000},"page":"941-945","source":"Crossref","is-referenced-by-count":3,"title":["Interleukin-6 Immunology in Macrophage Activation Syndrome Related to Neuroimmunological Diseases"],"prefix":"10.2169","volume":"64","author":[{"given":"Taichi","family":"Nomura","sequence":"first","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Niino","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Odani","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Amino","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusei","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zen-ichi","family":"Tanei","sequence":"additional","affiliation":[{"name":"Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12: 259-268, 2016.","DOI":"10.1038\/nrrheum.2015.179"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 64: 1680-1688, 2012.","DOI":"10.1002\/art.33496"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36: 135-141, 2011.","DOI":"10.1016\/j.jaut.2010.12.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord 27: 565-568, 2017.","DOI":"10.1016\/j.nmd.2017.03.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Uzawa A, Akamine H, Kojima Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol 358: 577634, 2021.","DOI":"10.1016\/j.jneuroim.2021.577634"},{"key":"6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","volume":"183","author":"PO Barros","year":"2016","unstructured":"6. Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol 183: 480-489, 2016.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7: e841, 2020.","DOI":"10.1212\/NXI.0000000000000841"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19: 402-412, 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cohen-Kaminsky S, Delattre RM, Devergne O, et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann N Y Acad Sci 681: 97-99, 1993.","DOI":"10.1111\/j.1749-6632.1993.tb22873.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jia D, Zhang F, Li H, et al. Responsiveness to tocilizumab in anti-acetylcholine receptor-positive generalized myasthenia gravis. Aging Dis 15: 824-830, 2024.","DOI":"10.14336\/AD.2023.0528"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yang TT, Wang ZY, Fan ZX, et al. A pilot study on tocilizumab in very-late-onset myasthenia gravis. J Inflamm Res 16: 5835-5843, 2023.","DOI":"10.2147\/JIR.S423098"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 83: 339-340, 2012.","DOI":"10.1136\/jnnp.2011.241760"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol 17: 145-157, 2021.","DOI":"10.1038\/s41584-020-00571-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 42: 712-722, 2015.","DOI":"10.3899\/jrheum.140288"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamabe T, Ohmura SI, Uehara K, Naniwa T. Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol 32: 169-176, 2022.","DOI":"10.1080\/14397595.2021.1899565"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Adachi S, Takase-Minegishi K, Maeda A, et al. Risk of macrophage activation syndrome in patients with adult-onset Still's disease treated with IL-1 and IL-6 inhibitors: a meta-analysis and single-center experience. Rheumatol Ther 10: 1623-1636, 2023.","DOI":"10.1007\/s40744-023-00600-x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsuura-Otsuki Y, Hanafusa T, Igawa K, Sato H, Nishizawa A, Yokozeki H. Macrophage activation syndrome triggered by disseminated tuberculosis with tuberculous gumma in a patient with adult-onset Still's disease and Good's syndrome. Eur J Dermatol 26: 309-311, 2016.","DOI":"10.1684\/ejd.2016.2745"},{"key":"18","unstructured":"18. Huang NH, Lien LM, Chen WH. Macrophage activation syndrome in a case of myasthenia gravis with concurrent cytomegalovirus infection. Acta Neurol Taiwan 29: 114-118, 2020."},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Frederiksen JK, Ross CW. Cytomegalovirus-associated hemophagocytic lymphohistiocytosis in a patient with myasthenia gravis treated with azathioprine. Blood 123: 2290, 2014.","DOI":"10.1182\/blood-2014-01-548172"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3757-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:31:10Z","timestamp":1742009470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3757-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3757-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"article-number":"3757-24"}}